Movement Alert｜Natera Falls 3.09% in Regular Trading, Profit-Taking Returns Despite Higher Price Target

Market Focus10-16

On October 16, Natera fell 3.09% in Regular Trading, trading at $392.64 per share, with turnover of $43.5993 million.

The move came even after Morgan Stanley raised its price target on Natera to $435 from $355 and maintained an Overweight rating, as the stock faced renewed short-term profit-taking pressure following a strong earlier run.

Recent company developments remained constructive: Natera’s multi-cancer early detection assay received FDA Breakthrough Device Designation, Signatera was approved in Japan as a companion diagnostic for muscle-invasive bladder cancer, and the company has continued advancing skin cancer and breast cancer clinical programs. Earlier, Natera reported second-quarter revenue of $752.8 million, up 37.7% year over year, and raised full-year revenue guidance to $2.85 billion to $2.91 billion. Even so, weakness across biotechnology shares, including a sharp decline in Moderna, appeared to weigh on near-term sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment